Relevant bibliographies by topics / Second-line therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Second-line therapy'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Second-line therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Second-line therapy"

1

Murphy, Richard A., Henry Sunpath, Carmen Castilla, et al. "Second-Line Antiretroviral Therapy." JAIDS Journal of Acquired Immune Deficiency Syndromes 61, no. 2 (2012): 158–63. http://dx.doi.org/10.1097/qai.0b013e3182615ad1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Calmy, Alexandra, Fernando Pascual, and Nathan Ford. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329. http://dx.doi.org/10.1016/s0140-6736(04)16716-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kulwichit, Wanla. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 329–30. http://dx.doi.org/10.1016/s0140-6736(04)16717-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Carr, Andrew. "First-line and second-line antiretroviral therapy." Lancet 364, no. 9431 (2004): 330. http://dx.doi.org/10.1016/s0140-6736(04)16718-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Weiss, Jared M., and Thomas E. Stinchcombe. "Second‐Line Therapy for Advanced NSCLC." Oncologist 18, no. 8 (2013): 947–53. http://dx.doi.org/10.1634/theoncologist.2013-0096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brandt, Kenneth D. "Second-line drug therapy for osteoarthritis." Clinical Medicine 1, no. 2 (2001): 110–12. http://dx.doi.org/10.7861/clinmedicine.1-2-110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Martin, Mike G., Ramaswamy Govindan, and Daniel Morgensztern. "Second-line therapy for esophageal cancer." Expert Review of Anticancer Therapy 7, no. 6 (2007): 871–76. http://dx.doi.org/10.1586/14737140.7.6.871.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hamers, Raph L. "Dolutegravir for second-line antiretroviral therapy." Lancet Infectious Diseases 19, no. 3 (2019): 218–19. http://dx.doi.org/10.1016/s1473-3099(19)30035-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ahmed, Mili, Douma Rabiâa, Jarrar Emna, et al. "Second-Line Therapy in Multiple Sclerosis." Multiple Sclerosis and Related Disorders 37 (January 2020): 101586. http://dx.doi.org/10.1016/j.msard.2019.11.061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bachner, Mark, and Maria De Santis. "Second-line therapy in bladder cancer." Current Opinion in Urology 19, no. 5 (2009): 533–39. http://dx.doi.org/10.1097/mou.0b013e32832eb473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Second-line therapy"

1

Mhangwane, Shushu Rirhandzu Comfort. "Predicting early and late first-line antiretroviral therapy virologic failure, and switch to second-line therapy in a military population in South Africa." Diss., University of Pretoria, 2018. http://hdl.handle.net/2263/64177.

Full text
Abstract:
The study involved retrospective data analysis using statistical methods to re-analyse data collected during a long-term study in a Human Immunodeficiency Virus infected population of South African National Defence Force employees and their dependents, where different parameters related to treatment and disease status of HIV infected patients were collected. This study attempted to identify possible predictors of both early and late occurrence of first-line antiretroviral therapy virologic failure, potential predictors of first-line antiretroviral virologic failure and for switching to second
APA, Harvard, Vancouver, ISO, and other styles
2

Court, Richard Gray. "Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy." Master's thesis, University of Cape Town, 2015. http://hdl.handle.net/11427/13801.

Full text
Abstract:
The management of patients failing second line antiretroviral therapy (ART) is a critical area of study considering the increasing numbers of patients on second line regimens, and the expense and poor availability of third line ART. Most patients who experience virologic failure (VF) on second line ART in low-middle income countries fail due to poor adherence rather than antiretroviral resistance. Pharmacy refill is an easily implementable adherence measure which has shown to correlate with viral load monitoring and survival, and has potential over the short term to be used as a simple adheren
APA, Harvard, Vancouver, ISO, and other styles
3

Mgosha, Peter Charles. "Barriers to Switching Patients to Second-Line Antiretroviral Treatment Among Clinicians in Tanzania." ScholarWorks, 2017. https://scholarworks.waldenu.edu/dissertations/3535.

Full text
Abstract:
Poor decision making among clinicians to transferring human immune deficiency virus (HIV) patients into second-line antiretroviral therapy (ART) has led to an increase in morbidity and mortality to people living with HIV (PLHIV). No clear barriers are known for clinicians not switching their patients. This is a descriptive qualitative research aimed to discover obstacles that influence clinicians' decision making to transferring patients into second-line ART despite higher level resistance to first-line ART. The researcher applied a participatory action research framework to solve the identifi
APA, Harvard, Vancouver, ISO, and other styles
4

Johnstone, Victoria. "Second-line antiretroviral therapy in a South African treatment programme : exploring determinants of switching and treatment outcomes." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.590631.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Namukanja, Phoebe Monalisa-Mayambala. "Adverse effects on second-line highly active antiretroviral therapy (HAART) among HIV infected adults and children treated at Mildway Uganda." Thesis, University of Limpopo (Medunsa Campus), 2011. http://hdl.handle.net/10386/532.

Full text
Abstract:
Thesis (MPH) -- University of Limpopo (Medunsa Campus), 2011.<br>Background Available and affordable second-line antiretroviral treatment regimens are a key component of universal access to treatment and its continuation. However, providing second-line ART is affected by a number of factors including infrastructure, skills and cod competency of available personnel, cost and availability of second-line drugs. Like first-line antiretroviral agents, second-line drugs have also inherent toxicities. While these have been described in adults, few studies reported this in children. Hence, the need
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Mei Hui. "A systematic review of the blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension." Thesis, University of British Columbia, 2009. http://hdl.handle.net/2429/12393.

Full text
Abstract:
Context: Although other factors independent of their blood pressure (BP) lowering effect may contribute to the reduction in morbidity and mortality associated with antihypertensive drugs, efficacy of an antihypertensive treatment is gauged by the magnitude of BP reduction. Diuretics are widely prescribed for hypertension not only as first-line monotherapy but also second-line in combination therapy. Therefore, it is essential to determine the effects of diuretics on BP, heart rate (HR) and withdrawals due to adverse effects (WDAEs) when used second-line for hypertension. Objectives: 1) To quan
APA, Harvard, Vancouver, ISO, and other styles
7

Meßner, Martina [Verfasser], and Johanna [Akademischer Betreuer] Pachmayr. "Sorafenib resistance of hepatocellular carcinoma : antibiotics second-line to Sorafenib therapy inhibit mitochondrial biogenesis and prevent tumor growth resumption / Martina Meßner ; Betreuer: Johanna Pachmayr." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2020. http://d-nb.info/1216417946/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Park, Su-In [Verfasser]. "Gemcitabin und Paclitaxel als Second-Line-Therapie beim fortgeschrittenen oder metastasierten Urothel-Karzinom / Su-In Park." Bonn : Universitäts- und Landesbibliothek Bonn, 2012. http://d-nb.info/1043698728/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kröber, Vinzenz [Verfasser], M. [Akademischer Betreuer] Lommatzsch, K. [Akademischer Betreuer] Jordan, and W. [Akademischer Betreuer] Schütte. "Phase I/II-Studie : Kombinationschemotherapie mit Docetaxel und Pemetrexed in der Second-Line-Therapie bei Patienten mit nichtkleinzelligem Bronchialkarzinom, Stadium IIIB und IV / Vinzenz Kröber. Betreuer: M. Lommatzsch ; K. Jordan ; W. Schütte." Halle, Saale : Universitäts- und Landesbibliothek Sachsen-Anhalt, 2015. http://d-nb.info/1075492904/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gaspar, Frederico Manuel Gomes Forte Portugal. "Chronic graft-versus-host disease : second line therapy review." Master's thesis, 2017. http://hdl.handle.net/10451/31315.

Full text
Abstract:
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2017<br>Graft-versus-Host disease (GVHD) is a complication of bone marrow transplant. It has two forms: acute and chronic. In this work we’ll only address the chronic one (cGVHD). cGVHD is a very frequent complication of the transplant (up to 50% of the patients) and a major one, given its high mortality rate, being the main cause of death in these patients, apart from the recurrence of the primary malignancy. Even thought our understanding of GVHD is far from complete, some progresses ar
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Second-line therapy"

1

C, Hyde, National Co-ordinating Centre for HTA (Great Britain), and Health Technology Assessment Programme, eds. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: A technology assessment. Core Research on behalf of the NCCHTA, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dixon, J. S. Second-line Agents in the Treatment of Rheumatic Diseases (Inflammatory Disease and Therapy). Informa Healthcare, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cimpean, Anca Maria, Andreea Adriana Jitariu, and Marius Raica. Growth Factors and Their Corresponding Receptors as Targets for Ovarian Cancer Therapy. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0011.

Full text
Abstract:
Ovarian cancer remains one of the most aggressive and difficult to manage malignancies regarding evaluation and therapeutic options. The high mortality persists despite extensive research in the field. Current conventional chemotherapy does not improve disease-free survival and does not decrease recurrences amongst patients. This calls for a stringent reconsideration of the drugs selection, focused on the most targeted strategies and personalization of the therapy. Targeted agents against growth factors and their corresponding receptors are already approved as first- or second-line neoadjuvant
APA, Harvard, Vancouver, ISO, and other styles
4

Dougherty, Darin D., Scott L. Rauch, and Michael A. Jenike. Treatments for Obsessive-Compulsive Disorder. Oxford University Press, 2015. http://dx.doi.org/10.1093/med:psych/9780199342211.003.0017.

Full text
Abstract:
There is overwhelming evidence of the most rigorous type supporting the efficacy of serotonin reuptake inhibitors (SRIs) in the treatment of obsessive-compulsive disorder (OCD). Along with SRIs, behavior therapy must be considered a viable first-line therapy. The best available data suggest that behavior therapy, and perhaps cognitive therapy, is at least as effective as medication in some instances and may be superior with respect to risks, costs, and enduring benefits. A variety of second-line medication treatments for OCD have been studied in a controlled or systematic fashion. Augmentation
APA, Harvard, Vancouver, ISO, and other styles
5

Reim, Bernd. Mitomycin C als "Second-line-Therapie" beim fortgeschrittenen metastasierten kolorektalen Karzinom. 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wong, Han Hsi, Basma Greef, and Tim Eisen. Treatment of metastatic renal cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0089.

Full text
Abstract:
Metastatic renal cancer is resistant to standard chemotherapy. Although some patients with indolent disease can be initially managed with observation, the majority of patients will require aggressive treatment soon after diagnosis. Options include cytoreductive nephrectomy, resection of a solitary metastasis in highly selected cases, or systemic therapy options. The TKIs sunitinib and pazopanib are currently the first-line treatments of choice. Whilst axitinib and cabozantinib have important roles in the second line the PD-1 checkpoint inhibitor, nivolumab, is now established as standard secon
APA, Harvard, Vancouver, ISO, and other styles
7

Dougherty, Darin D., Scott L. Rauch, and Michael A. Jenike. Pharmacological Treatments for Obsessive Compulsive Disorder. Edited by Gail Steketee. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195376210.013.0061.

Full text
Abstract:
Progress in treating OCD has accelerated in recent years. Effective first-line treatments include behavior therapy and medications, with overwhelming evidence supporting the efficacy of serotonergic reuptake inhibitors (SRIs). Second-line medication treatments for OCD include augmentation of SRIs with neuroleptics, clonazepam, or buspirone, with limited support for other strategies at present. Alternative monotherapies (e.g., buspirone, clonazepam, phenelzine) have more limited supporting data and require further study. Behavior therapy, and perhaps cognitive therapy, is as effective as medica
APA, Harvard, Vancouver, ISO, and other styles
8

Asherson, Philip, and Josep Antoni Ramos-Quiroga. Treatment in adult ADHD. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198739258.003.0046.

Full text
Abstract:
The treatment of ADHD in adults is very similar to that recommended for children and adolescents. There have been many more clinical trials evaluating the efficacy and safety of the drugs used in ADHD treatment on children than adults. Pharmacotherapy for adults with ADHD has been shown to be effective. The National Institute of Health and Care Excellence (NICE) guidelines recommend pharmacotherapy as first-line treatment for adult ADHD. The NICE guidelines consider stimulants (methylphenidate and dexamfetamine) as the first choice for treatment of adult ADHD, and the non-stimulant atomoxetine
APA, Harvard, Vancouver, ISO, and other styles
9

Huntoon, Kristin, and J. Bradley Elder. High-Grade Gliomas. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0001.

Full text
Abstract:
Glioblastoma is the most common primary malignant brain tumor. This chapter discusses the clinical presentation and initial workup for a patient with a suspected glioblastoma, as well as the optimal treatment strategy and prognosis. Diagnosis is typically made using magnetic resonance imaging. Optimal treatment involves maximal safe surgical resection followed by adjuvant chemotherapy and radiation therapy. Surgical adjuncts including intraoperative imaging modalities and brain mapping techniques help improve neurologic morbidity associated with surgery. Despite maximal treatment, virtually al
APA, Harvard, Vancouver, ISO, and other styles
10

Niaudet, Patrick, and Alain Meyrier. Minimal change disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0056_update_001.

Full text
Abstract:
Minimal change disease is characteristically responsive to high-dose corticosteroids. As this is the most common cause of nephrotic syndrome in children, and responses are usually prompt, response to 60 mg/m2/day of oral prednisolone (max. 80 mg) is often used as a diagnostic test. Adults respond more slowly and have a wider differential diagnosis, and often a high risk of side effects, so therapy is not recommended without confirmation by renal biopsy. Then first-line treatment is again prednisolone or prednisone, at 1 mg/kg/day (max. 60 mg). KDIGO and other treatment protocols recommend 6 we
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Second-line therapy"

1

Lamprecht, Peter, and Paul Klenerman. "Rituximab in Cryoglobulinemic Vasculitis: First- or Second-Line Therapy?" In HCV Infection and Cryoglobulinemia. Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1705-4_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Axon, A. "Quadruple therapy should be second-line treatment for Helicobacter pylori infection." In Helicobacter pylori. Springer Netherlands, 2000. http://dx.doi.org/10.1007/978-94-011-3927-4_68.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Collier, Ann C., and Margot A. Schwartz. "Strategies for Second-Line Antiretroviral Therapy in Adults with HIV Infection." In Antiviral Chemotherapy 5. Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-4743-3_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Roden, Dylan F., Jennifer M. Johnson, Petr Szturz, Paolo Bossi, and Athanassios Argiris. "New and Promising Targeted Therapies in First and Second-Line Settings." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_18.

Full text
Abstract:
AbstractDeeper understanding of the molecular pathogenesis of malignancies, including head and neck squamous cell carcinoma (HNSCC), has led to the investigation of several novel targeted therapies. These therapeutic approaches may eventually replace or complement existing treatment modalities, such as surgery, radiation therapy, and traditional cytotoxic chemotherapy. Epidermal growth factor receptor (EGFR) inhibitors, and specifically cetuximab, are as of now the only class of targeted agents, excluding immune checkpoint inhibitors, with approval in the treatment of HNSCC. Beyond EGFR inhibi
APA, Harvard, Vancouver, ISO, and other styles
5

Vannucchi, Alessandro M. "Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options." In Myeloproliferative Neoplasms. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-24989-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bettocchi, Carlo, Fabio Castiglione, Omer Onur Cakir, Ugo Falagario, and Anna Ricapito. "Erectile Dysfunction, Surgical and Regenerative Therapy." In Practical Clinical Andrology. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11701-5_5.

Full text
Abstract:
AbstractErectile dysfunction (ED) is defined as the failure to achieve and/or maintain a penile erection that is satisfactory for sexual intercourse.The implantation of a penile prosthesis may be considered in patients who are not suitable for different pharmacotherapies and do not respond to the first and the second line of medical treatment.Intraoperative complications include hematoma formation, floppy glans, perforation of the corpora cavernosa, and urethral injury. Bladder, vascular, and bowel injury are the most dangerous events and should be prevented. Postoperative complications are re
APA, Harvard, Vancouver, ISO, and other styles
7

Kulkarni, Harshad R. "PSMA Radioligand Therapy: A Revolution in the Precision Radiomolecular Oncology of Prostate Cancer." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_18.

Full text
Abstract:
AbstractThe incidence of prostate cancer is ever increasing. After various time intervals, the disease almost always becomes resistant to the standard hormone treatment (castration-resistant prostate cancer, CRPC). Most patients with CRPC either already have metastases at diagnosis or develop them during the early months of follow-up, which is associated with a relatively poor prognosis. The taxane-based chemotherapy for metastatic CRPC (mCRPC), first line with docetaxel and second line using cabazitaxel, are associated with a high incidence of adverse effects. The novel androgen-axis drugs (N
APA, Harvard, Vancouver, ISO, and other styles
8

Glass, Bertram, and Marie José Kersten. "Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma." In The EBMT/EHA CAR-T Cell Handbook. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-94353-0_12.

Full text
Abstract:
AbstractThe outcome of patients with large B cell lymphoma (LBCL) who did not respond to a classical immunochemotherapy regimen at any time or relapsed within 1 year following chemoimmunotherapy is poor. The Scholar-One-Study showed long-term event-free survival for less than 20% of these patients (Crump et al. 2017). The introduction of chimeric antigen receptor T cell therapy (CAR-T) is a substantial advancement for these patients, offering long-term remission and a curative prospect for 30 to 40% of patients (summarized in Table 12.1), (Abramson et al. 2020; Neelapu et al. 2017; Schuster et
APA, Harvard, Vancouver, ISO, and other styles
9

Wild, Damian. "Theranostics with Somatostatin Receptor Antagonists." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_35.

Full text
Abstract:
AbstractSomatostatin receptors (SST), especially SST subtype 2 (SST2), are important targets for the management of patients with neuroendocrine tumours (NETs) or neuroendocrine neoplasias (NENs). Peptide receptor radionuclide therapy (PRRT) with 177Lu-labelled SST agonists, for example, 177Lu-DOTA-TOC or 177Lu-DOTA-TATE, is recommended by the European Neuroendocrine Tumour Society as second-line treatment after progression under treatment with somatostatin analogues in patients with metastatic, SST positive grade 1 and 2 midgut NETs. PET/CT imaging with 68Ga-labelled SST agonists, for example,
APA, Harvard, Vancouver, ISO, and other styles
10

Kramer, D., N. Golz, D. Glaser, and H. Mast. "Treosulfan als Second-Line-Therapie beim fortgeschrittenen Ovarialkarzinom." In Gynäkologie und Geburtshilfe 1990. Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76124-9_111.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Second-line therapy"

1

Arentz, Matthew, Patricia Pavlinac, Michael E. Kimerling, David J. Horne, and Judd L. Walson. "Impact Of Antiretroviral Therapy In Patients With Drug Resistant Tuberculosis Requiring Second Line Therapy." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1822.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tiwari, Mani, Mahendra Patel, and Khyati Shamaliya. "Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2710.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dooper, Marten. "No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy." In ESMO Congress 2023, edited by Stefan Rauh. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/0b543d83.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Soto, CM Valencia, R. López-Sepúlveda, F. Artime-Rodríguez-Hermida, et al. "4CPS-103 Second-generation tyrosin kinase inhibitors in front-line therapy. comparing responses." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.194.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Choudhury, Saswata Paul, Patrick R. LaFontaine, Kalpesh Chatterjee, et al. "703 Shifting landscapes: impact of first-line immuno-oncology therapy on second-line docetaxel treatment in metastatic NSCLC." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.0703.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hölters, Sebastian, Lothar Bergmann, Viktor Grünwald, et al. "Abstract 901: Plasma proteins characterize second-line therapy response in progressive renal cell carcinoma." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-901.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fyles, Fred, Amy Nuttall, Hannah Joplin, Laura Watkins, and Hassan Burhan. "Switching things up: experience of second line anti-interleukin-5 therapy for severe asthma." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa4100.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Liou, Jyh-Ming, Po-Yueh Chen, Chieh-Chang Chen, et al. "IDDF2019-ABS-0126 Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of helicobacter pylori -a multicenter randomized trial." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Backes, Floor, Tirza Areli Calderón Boyle, Jessica Perhanidis, et al. "2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?" In ESGO 2022 Congress. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-esgo.551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Howden, Adam, and Talal Valliani. "P023 The effective use of bezafibrate as a second line therapy for primary biliary cholangitis." In Abstracts of the British Association for the Study of the Liver Annual Meeting, 22–24 November 2021. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2021. http://dx.doi.org/10.1136/gutjnl-2021-basl.32.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Second-line therapy"

1

Zhang, Lin-Ming, Xuan-ling Xing, Bing-ran Zhang, et al. Efficacy of Rituximab as Second-Line Therapy for Autoimmune Encephalitis: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.9.0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gu, Hongmei, Yidan Wang, Guomei Tai, Qiuxing Yang, Jia Liu, and Xiying Shen. Comprehensive curative effect of targeting PD-1 or traditional single-agent chemotherapy in second-line therapy for terminal or metastatic esophageal cancer：A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.7.0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Chunyan, Yujia Chen, Rui Rao, Yihui Chai, Yunzhi Chen, and Wen Li. Association of metformin use with asthma development and adverse outcomes: a systematic review and meta-analysis of observational studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.4.0005.

Full text
Abstract:
Review question / Objective: 1 Whether metformin can reduce the incidence of asthma in patients with T2D. 2 Whether T2D patients with concurrent asthma can safely use metformin to reduce adverse outcomes. Condition being studied: Recent epidemiological studies suggest that metformin, the first-line medication used for T2D patients, may reduce the risk of asthma exacerbations. Therefore, this article aims to explore two research questions: first, whether metformin can reduce the incidence of asthma in patients with T2D, and second, whether T2D patients with concurrent asthma can safely use metf
APA, Harvard, Vancouver, ISO, and other styles
4

Shujaa, Asaad Suliman, and Qasem Almulihi. The efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations, A systemic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.11.0011.

Full text
Abstract:
Review question / Objective: This study is to assess the efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations. Rationale: Refractory status epilepticus (RSE) is either generalized or complex partial status epilepticus (SE) that fails to respond to first and second-line therapies. Super refractory status epilepticus (SRSE) is SE that remains unresponsive despite 24 hours of therapy with general anesthesia [1, 2]. Both RSE and SRSE pose significant challenges for the managing intensivist. There exists a race against tim
APA, Harvard, Vancouver, ISO, and other styles
5

Sembler, Jose Ignacio, Diether Beuermann, Carlos Elías, and Cheryl Gray. IDB-9: Country Programming. Inter-American Development Bank, 2013. http://dx.doi.org/10.18235/0010515.

Full text
Abstract:
This paper analyzes whether IDB-9 requirements surrounding the country programming process of the Inter-American Development Bank (IDB, or Bank) are being implemented fully and effectively. The country programming process includes two documents: the Country Strategy, which provides a multiyear overview of the Bank¿s work program; and an annual document that lays out lending allocations and the work program. The main requirements of IDB-9 related to country programming are that Country Strategies include development and macro-fiscal frameworks, that they build on these frameworks and country di
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Second-line therapy' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography